If you've been keeping an eye on cardiac device innovation lately, you've probably noticed something: babies born with structural heart problems are getting better, safer treatment options than ever before. That shift is driving real momentum in the congenital heart valve devices market, as engineers rethink what a replacement or repair valve can look like when the patient is the size of a...
Picture a disease that mostly shows up late in life, often in patients already juggling several other health conditions, and you've got a good starting point for understanding bullous pemphigoid. It's a chronic autoimmune condition where the body's own immune system turns on basement membrane proteins like BP180 and BP230, setting off complement activation and eosinophil-driven inflammation....
Here's something worth paying attention to: the science of making vaccines work better is quietly becoming one of the fastest-growing corners of global healthcare. Between 2024 and 2030, the vaccine adjuvants market is set to climb at a CAGR of 12.91% — a pace driven by rising rates of infectious disease and cancer, gaps in existing vaccine coverage, and a worldwide push to get more...
Wound closure might seem like the least glamorous corner of medtech, but the numbers tell a different story. The surgical sutures market is set to nearly double in less than a decade, moving from USD 6.03 billion in 2025 to USD 11.52 billion by 2034 — a 7.57% CAGR from 2026 to 2034. Behind that curve sit a few unglamorous but powerful forces: more surgeries being performed every...
Porphyria isn't a single disease — it's a family of rare metabolic disorders, inherited or acquired, that stem from glitches in how the body produces heme, the essential building block of hemoglobin. Because heme synthesis unfolds across several steps in the liver and bone marrow, even a single disruption can trigger a cascade of symptoms as porphyrins or their precursors build up in the...
Cancer immunotherapy has a new name generating buzz beyond PD-1 and PD-L1: TIGIT, short for T-cell immunoreceptor with Ig and ITIM domains. Sitting on the surface of activated T cells, natural killer cells, and regulatory T cells, TIGIT locks onto the ligands CD155 and CD112, which tumors use to keep the immune system quiet. Block that handshake, and CD226 signaling on NK and CD8+ T cells...
Pain touches almost everyone at some point, but for hundreds of millions of people worldwide it's not a passing inconvenience — it's a daily reality. That's precisely why the pain management market is drawing so much attention right now. As opioid concerns push clinicians toward safer alternatives, device-based therapies are stepping into the spotlight, and the numbers back it up: the...
The neurology devices market is forecast to expand at a CAGR of 7.46% from 2024 to 2030, a trajectory underpinned by structural demographic and epidemiological shifts rather than short-term demand fluctuations. Global dementia prevalence stood at approximately 55 million cases in 2020, per WHO estimates, while Parkinson's disease affected an estimated 8.5 million individuals in 2019....
Picture a disease that quietly steals the center of someone's vision, injection by injection, year after year. That's the reality for millions living with abnormal vessel growth beneath the retina, and it's why the choroidal neovascularization market has become one of the more closely watched corners of ophthalmology. What was once a story about managing a chronic condition is turning into a...
Nearly a third of adults in the US now live with pain that just won't quit — and that reality is reshaping an entire industry. CLBP full form simply refers to Chronic Lower Back Pain: discomfort in the lower back that sticks around for 12 weeks or more, often long after any injury should have healed. It's now one of the biggest drivers of disability on the planet, hitting older adults...
For decades, people living with nonalcoholic steatohepatitis had no approved pharmacological option — only lifestyle changes and watchful waiting while their liver disease quietly progressed. That changed when the FDA granted accelerated approval to resmetirom, marketed as Rezdiffra, for adults with noncirrhotic NASH and moderate-to-advanced fibrosis. It marked a genuine turning point:...
For decades, doctors treating fatty liver disease had no approved medicine to offer — only advice about diet, exercise, and watchful waiting. That changed in March 2024, when the FDA approved REZDIFFRA (resmetirom), becoming the first drug ever cleared specifically for nonalcoholic steatohepatitis (NASH), also known by its newer clinical name, MASH (metabolic dysfunction-associated...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)